| Authors: |
Weisberg E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA. ellen_weisberg@dfci.harvard.edu., Chowdhury B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA., Garg S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Department of Molecular Genetics, Erasmus Medical Center, Rotterdam., Akatsu T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Ni W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA., Gokhale PC; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA., Eschle BK; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA., Grant S; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA., Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA., DeCaprio JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA., Nöltner L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Molecular Oncology, Faculty of Medicine, University of Leipzig, Leipzig, Germany., Garcia J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA., Marinchev K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Galinsky I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Nath A; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA., Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA. |
